All Articles

As the COVID-19 pandemic stretches into its fifth month in the United States, advocacy groups providing support for patients with cancer are delivering essential support and services, while they worry about the long-term psychosocial impact on these patients and the future of clinical trials.

As we learn more about the complicated behavior of the COVID-19 virus, we have come to understand that overactivation of the patient’s own immune system can often be the most dangerous factor. In this webcast, top cancer experts discuss the latest studies investigating using anti-cancer therapies as treatments for COVID-19. What are some of the options and where does the research stand today?

The COVID-19 pandemic has led to the elimination of several restrictions on telehealth and infusion therapy in the home setting. In this webcast, a panel of experts discuss the short- and long-term prospects for in-home infusion for patients with cancer. What are the benefits and drawbacks?

We are living in a time that is filled with multiple challenges. I want to bring to your attention that the Academy of Oncology Nurse & Patient Navigators (AONN+) has created a virtual toolkit of information for our membership regarding the COVID-19 pandemic.

At the 2020 virtual meeting of the American Association for Cancer Research (AACR), a group of oncologists working in different hot spots around the world gave a snapshot of wisdom gleaned from their experience thus far.

The authors advocate for nurse navigation services to guide patients through this challenging time in their lives.

On May 15, 2020, the FDA approved a new indication for the first immunotherapy combination with the PD-1 inhibitor nivolumab (Opdivo; BMS) and the CTLA-4 inhibitor ipilimumab (Yervoy; BMS) for the first-line treatment of adults with metastatic non–small-cell lung cancer (NSCLC) and PD-L1 expression of ≥1%, as determined by an FDA-approved test, but without EGFR or ALK genomic translocations.